These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6743780)

  • 1. Pharmacokinetic and clinical parameters of zopiclone and trimipramine when administered simultaneously to volunteers.
    Caille G; du Souich P; Spenard J; Lacasse Y; Vezina M
    Biopharm Drug Dispos; 1984; 5(2):117-25. PubMed ID: 6743780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A repeated dose pharmacokinetic study of a new hypnotic agent, zopiclone (Imovane).
    Houghton GW; Dennis MJ; Templeton R; Martin BK
    Int J Clin Pharmacol Ther Toxicol; 1985 Feb; 23(2):97-100. PubMed ID: 3988401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection.
    Abernethy DR; Greenblatt DJ; Shader RI
    Clin Pharmacol Ther; 1984 Mar; 35(3):348-53. PubMed ID: 6697642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem.
    Chouinard G; Lefko-Singh K; Teboul E
    Cell Mol Neurobiol; 1999 Aug; 19(4):533-52. PubMed ID: 10379424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of zopiclone.
    Fernandez C; Martin C; Gimenez F; Farinotti R
    Clin Pharmacokinet; 1995 Dec; 29(6):431-41. PubMed ID: 8787948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic.
    Goa KL; Heel RC
    Drugs; 1986 Jul; 32(1):48-65. PubMed ID: 2874974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency.
    Gaillot J; Le Roux Y; Houghton GW; Dreyfus JF
    Sleep; 1987; 10 Suppl 1():7-21. PubMed ID: 3438645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and metabolism of zopiclone.
    Gaillot J; Heusse D; Hougton GW; Marc Aurele J; Dreyfus JF
    Int Pharmacopsychiatry; 1982; 17 Suppl 2():76-91. PubMed ID: 7188377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma concentrations and central nervous system effects of the new hypnotic agent zopiclone in patients with chronic liver disease.
    Parker G; Roberts CJ
    Br J Clin Pharmacol; 1983 Sep; 16(3):259-65. PubMed ID: 6626417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone.
    Aranko K; Luurila H; Backman JT; Neuvonen PJ; Olkkola KT
    Br J Clin Pharmacol; 1994 Oct; 38(4):363-7. PubMed ID: 7833227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic characteristics of two different formulations of trimipramine determined with a new GLC method.
    Caillé G; Besner JG; Lacasse Y; Vézina M
    Biopharm Drug Dispos; 1980; 1(4):187-94. PubMed ID: 7448347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zopiclone concentrations in oral fluid and blood after, administration of therapeutic doses of zopiclone.
    Hjelmeland K; Gustavsen I; Øiestad EL; Øiestad ÅML; Høiseth G; Mørland J
    Forensic Sci Int; 2017 Sep; 278():177-183. PubMed ID: 28735217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentrations and effects of zopiclone are greatly reduced by rifampicin.
    Villikka K; Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
    Br J Clin Pharmacol; 1997 May; 43(5):471-4. PubMed ID: 9159561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-finding and premedication studies with zopiclone.
    Dundee JW; Elwood RJ; Hildebrand PJ; Singleton M
    Int Pharmacopsychiatry; 1982; 17 Suppl 2():210-5. PubMed ID: 7188375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.
    Najib J
    Clin Ther; 2006 Apr; 28(4):491-516. PubMed ID: 16750462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronopharmacokinetic and bioequivalence studies of two formulations of trimipramine after oral administration in man.
    Bougerolle AM; Chabard JL; Jbilou M; Dordain G; Eschalier A; Aumaitre O; Gaillot J; Piron JJ; Petit J; Berger JA
    Eur J Drug Metab Pharmacokinet; 1989; 14(2):139-44. PubMed ID: 2591418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone.
    Jalava KM; Olkkola KT; Neuvonen PJ
    Eur J Clin Pharmacol; 1996; 51(3-4):331-4. PubMed ID: 9010708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bitterness-Masking Effects of Different Beverages on Zopiclone and Eszopiclone Tablets.
    Yoshida M; Kojima H; Uda A; Haraguchi T; Ozeki M; Kawasaki I; Yamamoto K; Yano I; Hirai M; Uchida T
    Chem Pharm Bull (Tokyo); 2019; 67(5):404-409. PubMed ID: 31061364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure.
    Viron B; De Meyer M; Le Liboux A; Frydman A; Maillard F; Mignon F; Gaillot J
    Int Clin Psychopharmacol; 1990 Apr; 5 Suppl 2():95-104. PubMed ID: 2387982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and metabolism of zopiclone.
    Gaillot J; Heusse D; Hougton GW; Marc Aurele J; Dreyfus JF
    Pharmacology; 1983; 27 Suppl 2():76-91. PubMed ID: 6669634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.